New chickenpox vaccine shows promise in large Kids' trial
NCT ID NCT07054099
First seen Jun 26, 2026 · Last updated Jun 27, 2026 · Updated 1 time
Summary
This study tests a new chickenpox vaccine called MG1111 in healthy children aged 1 to 12 years. About 474 kids will receive either the new vaccine or the current one (Varivax) to compare safety and immune response. Participants will be followed for 42 days after each dose, and up to 10 years to see if they get chickenpox.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
- Active substance
- MG1111 (Barycela inj.) chickenpox vaccine
- What this could lead to
- If successful, this could provide a safe and effective alternative chickenpox vaccine for children, with protection lasting up to 10 years.
- What could go wrong
- This is a non-inferiority trial, meaning the new vaccine may not be better than the existing one. Also, long-term protection data is still being collected.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for CHICKENPOX VACCINE are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
Srinagarind Hospital
RECRUITINGKhon Kaen, Changwat Khon Kaen, 40002, Thailand
More trials for these conditions
Other studies related to the condition(s) this trial covers.